共 386 条
[1]
O’Donnell JS(2019)Cancer immunoediting and resistance to T cell-based immunotherapy Nat Rev Clin Oncol 16 151-167
[2]
Teng MWL(2016)Molecular and biochemical aspects of the PD-1 checkpoint pathway N Engl J Med 375 1767-1778
[3]
Smyth MJ(2015)Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer N Engl J Med 373 123-135
[4]
Boussiotis VA(2015)Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer N Engl J Med 373 1627-1639
[5]
Brahmer J(2017)Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet 389 255-265
[6]
Reckamp KL(2016)Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 387 1540-1550
[7]
Baas P(2019)Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater J Clin Oncol 37 537-546
[8]
Borghaei H(2019)How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer Ann Oncol 30 884-896
[9]
Paz-Ares L(2019)Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Lancet Respir Med 7 387-401
[10]
Horn L(2019)Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors Cancer Immunol Immunother 68 341-352